Source comparison
TB-500 Research REM Sleep Considerations: Dosing Protocols Comparison
Twice Weekly (2–5mg) +18–22 min延长 Days 5–8 (moderate) Days 11–14 (strong) Standard research protocol. Predictable arc, manageable disruption, clear rebound. Best balance of repair velocity and sleep preservation. Three Times Weekly (2–5mg) +15–19 min Days 6–9
This comparison does not assign a generated winner or score.
- Twice Weekly (2–5mg)
- +18–22 min延长
- Days 5–8 (moderate)
- Days 11–14 (strong)
- Standard research protocol. Predictable arc, manageable disruption, clear rebound. Best balance of repair velocity and sleep preservation.
- Three Times Weekly (2–5mg)
- +15–19 min
- Days 6–9 (moderate)
- Days 12–16 (moderate)
- Extended Phase 2 but reduced severity. Suitable for subjects prioritising sleep quality over accelerated repair timelines.
- Daily Dosing (1–2mg)
- +12–16 min (sustained)
- Continuous mild disruption
- Minimal (occurs post-cessation)
- Cytokines never fully clear between doses. Repair outcomes equivalent to twice-weekly but sleep architecture more consistently impaired throughout protocol.
- Morning Dosing (any schedule)
- +20–28 min (next night)
- Days 4–9 (severe)
- Days 13–17
- Cytokine peak coincides with sleep onset. 60% higher nocturnal awakening rate vs afternoon dosing. Avoid unless protocol requires AM administration.
- Afternoon Dosing (4–6pm, any schedule)
- +10–14 min
- Days 5–8 (mild-moderate)
- Optimal timing. Cytokine peak occurs pre-sleep, clearance aligns with natural REM dominance in late sleep cycles. Reduces fragmentation by 40–50%.